Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
39.41
+0.04 (0.10%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Company Description
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases.
It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren’s disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 315 |
| CEO | Eric Venker |
Contact Details
Address: 1000 Park Forty Plaza, Suite 210 Durham, North Carolina 27713 United States | |
| Phone | 917 410 3120 |
| Website | immunovant.com |
Stock Details
| Ticker Symbol | IMVT |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 1764013 |
| CUSIP Number | 45258J102 |
| ISIN Number | US45258J1025 |
| Employer ID | 83-2771572 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Khira Gabliani M.B.A. | Chief of Staff to the Chief Executive Officer |
| Dr. Eric Venker M.D., Pharm.D. | Chief Executive Officer and Director |
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
| Melanie Gloria B.S.N. | Chief Operating Officer |
| Christine Blodgett | Senior Vice President of Human Resources |
| Becky Merlina | Senior Vice President and Global Head of Quality |
| Yan Zheng M.S., Ph.D. | Senior Vice President of Biostatistics, Programming and Data Management |
| Sheetal Patel M.B.A., M.D., M.S. | Senior Vice President of Clinical Development |
| Ruby Grewal M.B.A. | Senior Vice President of Commercial |
| Luciano Pollastrini M.S. | Senior Vice President of CMC Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 22, 2026 | ARS | Filing |
| Jul 22, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 22, 2026 | DEF 14A | Other definitive proxy statements |
| Jun 26, 2026 | 144 | Filing |
| Jun 26, 2026 | 144 | Filing |
| Jun 26, 2026 | 144 | Filing |
| Jun 26, 2026 | 144 | Filing |
| Jun 15, 2026 | 144 | Filing |
| May 28, 2026 | 144 | Filing |
| May 20, 2026 | 144 | Filing |